News coverage about Anacor Pharmaceuticals (NASDAQ:ANAC) has been trending positive this week, Alpha One reports. The research group, a subsidiary of Accern, rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Alpha One ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Anacor Pharmaceuticals earned a media sentiment score of 0.31 on Alpha One’s scale. Alpha One also assigned headlines about the biopharmaceutical company an impact score of 83 out of 100, indicating that recent press coverage is very likely to have an effect on the stock’s share price in the near future.
Anacor Pharmaceuticals Company Profile
Anacor Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule therapeutics derived from its boron chemistry platform. Its lead product development candidate is crisaborole topical ointment, approximately 2%, a non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the treatment of mild-to-moderate atopic dermatitis and psoriasis.
Receive News & Ratings for Anacor Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anacor Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.